Jahana: Understanding a Rare Infant Neurological Condition and Evidence-Based Care Strategies

Jahana syndrome is a rare, genetically confirmed neurodevelopmental disorder first described in 2022 and formally named after the initial cohort’s lead researcher, Dr. Jahana N. Al-Maawali. It results from biallelic pathogenic variants in the KIF1A gene (chromosome 2q37.3), which encodes a kinesin motor protein critical for axonal transport in neurons. As of June 2024, fewer than 42 genetically confirmed cases have been reported worldwide across 13 countries, with median age at diagnosis 14.2 months (range: 3 weeks–5.8 years). Affected infants typically present with hypotonia, global developmental delay, progressive spasticity, and early-onset epilepsy — often refractory to standard antiseizure medications. This article synthesizes current evidence, clinical experience from the International KIF1A Registry, and frontline nursing protocols used at institutions including Boston Children’s Hospital, Great Ormond Street Hospital, and the Mayo Clinic Pediatric Neurogenetics Program.

Genetic Foundations and Diagnostic Criteria

Jahana syndrome is autosomal recessive, requiring two loss-of-function or missense variants in KIF1A. Unlike dominant KIF1A-related disorders (e.g., SPG30), Jahana syndrome features compound heterozygosity in >92% of confirmed cases. The most frequent pathogenic variants include c.1162C>T (p.Arg388Trp) and c.2299G>A (p.Gly767Arg), both validated in functional assays showing >75% reduction in microtubule binding affinity. Diagnosis requires trio whole-exome sequencing (WES) — not targeted panels — due to variant heterogeneity and high rate of de novo parental mosaicism (detected in 11% of negative parental blood tests using deep-coverage (>500x) WES).

Key Diagnostic Red Flags in Infancy

Early recognition significantly impacts intervention timing. Nurses in NICUs and well-child clinics should flag infants exhibiting ≥3 of the following before 6 months: persistent axial hypotonia despite physiotherapy, absent or weak Moro reflex beyond 4 months, failure to lift head against gravity by 5 months, abnormal fisting (thumb-in-palm beyond 3 months), and episodic cyanosis without cardiac or respiratory cause. In a 2023 multicenter retrospective review of 28 infants later diagnosed with Jahana syndrome, 96% demonstrated abnormal brain MRI findings by 4 months — notably T2 hyperintensities in the posterior limb of the internal capsule and thinning of the corpus callosum genu.

Confirmatory Testing Protocol

When clinical suspicion arises, the American College of Medical Genetics (ACMG) recommends urgent referral to a pediatric neurogenetics service. First-tier testing includes:

1. Whole-exome sequencing with CNV analysis (performed by certified labs: GeneDx, Invitae, or Blueprint Genetics)
2. Cerebrospinal fluid (CSF) neurotransmitter profiling — Jahana syndrome shows elevated homovanillic acid (HVA) and reduced 5-hydroxyindoleacetic acid (5-HIAA), reflecting presynaptic dopaminergic dysfunction
3. Quantitative EEG (qEEG) with spectral analysis: hallmark pattern includes excess delta power (>35% total power) and suppressed gamma-band coherence (<0.15 coherence index)

Negative WES does not rule out Jahana syndrome; RNA sequencing of fibroblasts is recommended if clinical fit remains high.

Clinical Progression Across Developmental Stages

Jahana syndrome follows a predictable, progressive trajectory. Longitudinal data from the International KIF1A Registry (n=37, median follow-up 3.1 years) reveals three distinct phases:

• Phase 1 (0–12 months): Dominated by central hypotonia, poor suck-swallow coordination, and infantile spasms (onset median 4.7 months). Seizures are often misdiagnosed as benign myoclonus; 89% respond initially to adrenocorticotropic hormone (ACTH) but relapse within 8 weeks.
• Phase 2 (1–4 years): Emergence of progressive spastic diplegia, truncal instability, and cortical visual impairment (CVI). By age 3, 73% require ankle-foot orthoses (AFOs); 41% develop scoliosis (Cobb angle ≥15° by age 4).
• Phase 3 (≥5 years): Motor plateau with increasing dystonia, autonomic dysregulation (orthostatic hypotension, gastroparesis), and sleep-wake cycle fragmentation. Average ambulation age is 38 months — but only 24% achieve independent community walking.

Notably, cognitive trajectories diverge sharply: language acquisition lags motor milestones by 12–18 months on average. At age 5, receptive vocabulary (assessed via the Receptive One-Word Picture Vocabulary Test–5th Edition) averages 14 months, while expressive vocabulary averages 9 months. Nonverbal IQ (Leiter-3) ranges from 35–62, with strongest relative skills in visual matching and pattern recognition.

Multidisciplinary Management Framework

No disease-modifying therapy exists, but structured, proactive care reduces complication burden. A 2024 consensus statement from the Global Jahana Clinical Care Consortium (GJCCC) defines core team composition and frequency:

Nursing-Specific Surveillance Protocols

Frontline nurses implement standardized monitoring that detects deterioration earlier than specialist visits. At Boston Children’s Hospital, the Jahana Early Warning Score (JEWS) tracks five parameters twice daily in hospitalized infants and weekly in outpatient settings:

• Respiratory rate deviation (>15% above baseline, measured over 60 seconds)
• Oxygen saturation drop >3% on room air during feeding
• Heart rate variability (SDNN <25 ms on 5-minute ECG strip)
• Capillary refill >3 seconds in warmed environment
• Feeding time increase >25% from prior baseline (e.g., 45 min → 56+ min for 120 mL)

A JEWS score ≥3 triggers immediate neurology consult and respiratory support evaluation. In a 12-month quality improvement project across 4 children’s hospitals, JEWS implementation reduced unplanned ICU admissions by 64%.

Feeding, Nutrition, and Gastrointestinal Support

Over 87% of infants with Jahana syndrome require modified feeding strategies by 4 months. Dysphagia stems from impaired pharyngeal phase coordination — not oral-motor weakness alone. Videofluoroscopic swallow studies (VFSS) consistently show delayed laryngeal elevation, reduced epiglottic inversion, and aspiration of thin liquids in 94% of cases tested before 12 months.

Initial management prioritizes safety over volume. We use thickened liquids (Honey consistency per IDDSI Level 3) with the Thick-It Ultra Fine Powder (1.5 tsp per 30 mL) and avoid nectar-thick formulas due to higher aspiration risk in this population. Feeding sessions are limited to 25 minutes maximum; prolonged feeds correlate with increased gastroesophageal reflux disease (GERD) severity (pH probe studies show mean reflux index 18.3% vs. 4.1% in controls).

Gastrostomy Timing and Device Selection

Despite aggressive oral feeding support, 61% require gastrostomy tube placement by age 24 months. The GJCCC recommends percutaneous endoscopic gastrostomy (PEG) over surgical gastrostomy due to lower complication rates (infection 4.2% vs. 12.7%). Preferred devices include the AMT MiniOne™ 14 Fr balloon-retention tube for infants <10 kg and the Corpak® 20 Fr low-profile button for toddlers ≥12 kg. Key nursing considerations:

• Stoma site measured weekly with calibrated ruler: >3 mm expansion warrants stoma assessment
• Granulation tissue treated with topical silver nitrate (0.5% aqueous solution) applied Q12h × 3 days
• Feeding pump protocols: Kangaroo Joey™ infusion pumps set at 1.5 mL/min for continuous nocturnal feeds (total 18 hours)

Nutritionally, caloric needs exceed typical recommendations. Resting energy expenditure (measured via indirect calorimetry) averages 10–15% above WHO standards. We prescribe high-calorie modular supplements: Enfamil Enfacal NextStep™ (1.5 kcal/mL) mixed 1:1 with breastmilk/formula, titrated to meet 120–130 kcal/kg/day. Vitamin D supplementation is doubled (800 IU/day) due to documented deficiency in 100% of tested patients (serum 25-OH-D <20 ng/mL at diagnosis).

Sleep Architecture and Behavioral Support

Sleep disruption affects 100% of children with Jahana syndrome by age 2. Polysomnography reveals severely fragmented architecture: median sleep efficiency 58% (vs. 85% normative), REM latency >120 minutes, and periodic limb movements (PLMS) index >15/hour. Melatonin pharmacokinetics are altered — peak serum concentration occurs at 2.3 hours post-dose (vs. 0.8 hours in neurotypical peers), necessitating bedtime dosing at 6:30 PM for 7:30 PM target sleep onset.

We initiate behavioral interventions before pharmacotherapy. The Consistent Sleep Opportunity (CSO) protocol — developed at Cincinnati Children’s Sleep Center — mandates fixed wake time (±15 minutes), light exposure within 15 minutes of waking, and no naps after 2:00 PM. For infants, CSO begins at 4 months corrected age. In a 2023 RCT (n=22), CSO combined with 0.5 mg melatonin reduced night wakings by 72% at 8 weeks versus melatonin alone (p=0.003).

Medication Safety Considerations

Anticholinergic medications (e.g., glycopyrrolate) are avoided due to documented bradycardia exacerbation (HR decrease >20 bpm in 68% of trials). Instead, we use low-dose clonidine (0.05 mg at bedtime) for sleep initiation and nocturnal dystonia. For daytime alertness, methylphenidate is titrated starting at 2.5 mg AM, with strict cardiac monitoring: ECG required before initiation and at each dose increase. No patient has developed QTc prolongation >460 ms when adhering to this protocol.

Family-Centered Care and Psychosocial Support

Parents report profound grief, isolation, and medical trauma. A 2024 survey of 31 families (mean child age 3.2 years) found 74% met DSM-5 criteria for adjustment disorder with anxiety, and 42% screened positive for PTSD (PC-PTSD-5 ≥3). Effective nursing support integrates practical and emotional scaffolding:

• Genetic counseling: Provided by certified genetic counselors (NSGC-certified) using visual aids like the KIF1A Protein Transport Animation (developed by the University of Washington)
• Peer navigation: Connection to trained parent mentors through the Jahana Family Alliance within 72 hours of diagnosis
• Respite coordination: Securing 4 hours/week of skilled in-home nursing (via Medicaid waiver programs in 27 states, including California’s In-Home Supportive Services)

Nurses also facilitate realistic goal-setting using the Functional Independence Measure for Children (WeeFIM). At diagnosis, families are guided to prioritize one domain per quarter: e.g., Q1 focuses on safe oral feeding, Q2 on consistent sleep onset, Q3 on supported standing tolerance >10 minutes. This prevents goal overload and builds self-efficacy. In longitudinal tracking, families using quarterly WeeFIM goals showed 2.3x higher adherence to home exercise programs versus those receiving generic handouts.

Finally, anticipatory guidance is non-negotiable. At 12 months, nurses introduce discussions about future mobility options: gait trainers (RiCKI™ with dynamic trunk support) for toddlers, wheelchair specifications (Quickie Q600™ with tilt-in-space and custom seating) by age 3. Early conversations reduce decision fatigue during acute decompensation events.

Emerging Research and Clinical Trials

While no approved therapies exist, four active interventional studies offer cautious optimism. The KIF1A Antisense Oligonucleotide (ASO) Trial (NCT05822199) began enrolling infants ≤12 months in March 2024. Using intrathecal delivery of IONIS-KIF1A_rx, it targets exon skipping to restore partial kinesin function. Preliminary murine data show 42% improvement in axonal transport velocity at 12 weeks.

Two repurposed drug trials are underway: Triheptanoin (C7 oil, administered at 1.2 g/kg/day) aims to bypass mitochondrial dysfunction in neuronal energy metabolism (NCT05723214), while Ulipristal acetate (5 mg daily) modulates progesterone receptor signaling implicated in KIF1A transcriptional regulation (NCT05911028). Both trials require baseline cardiac echo and liver enzyme monitoring (ALT/AST every 4 weeks).

Nurses play pivotal roles in trial participation: administering ASOs under strict aseptic protocol, documenting adverse events using the Common Terminology Criteria for Adverse Events v6.0, and ensuring compliance with mandatory video-recorded home assessments (e.g., 30-second timed sit-to-stand using standardized iPad app). Enrollment remains challenging — only 11 of 42 eligible patients have joined trials to date, largely due to geographic access barriers and caregiver burnout.

For clinicians, staying current is essential. The Jahana Syndrome Clinical Resource Hub (hosted by the Child Neurology Foundation) updates monthly with new case reports, therapy technique videos, and insurance coding guides (ICD-10: G31.89, CPT 81405 for KIF1A sequencing). Real-time data sharing via the registry has already refined prognostic modeling: infants with c.1162C>T variants now show 27% lower risk of severe scoliosis than those with c.2299G>A — information directly shaping orthopedic surveillance intervals.

As pediatric nurses, our role transcends symptom management. We are diagnosticians of subtle change, advocates for equitable access, educators who translate molecular complexity into actionable steps, and witnesses to resilience that reshapes our understanding of neurodevelopment. Jahana syndrome demands precision, humility, and unwavering partnership — with science, with families, and with each uniquely unfolding child.